Autonomix Medical, Inc. (NASDAQ:AMIX) Short Interest Up 327.2% in July

Autonomix Medical, Inc. (NASDAQ:AMIX) was the recipient of a large growth in short interest in July. As of July 31st, there was short interest totaling 263,441 shares, a growth of 327.2% from the July 15th total of 61,662 shares. Currently, 28.9% of the company’s stock are sold short. Based on an average trading volume of 7,539,029 shares, the short-interest ratio is presently 0.0 days.

Autonomix Medical Price Performance

AMIX stock traded down $0.78 during trading hours on Thursday, reaching $6.75. The stock had a trading volume of 238,572 shares, compared to its average volume of 1,562,391. Autonomix Medical has a fifty-two week low of $2.44 and a fifty-two week high of $32.55. The stock has a market capitalization of $6.55 million, a PE ratio of -0.09 and a beta of -1.17. The stock has a 50-day simple moving average of $6.86 and a 200 day simple moving average of $7.76.

Autonomix Medical (NASDAQ:AMIX) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($5.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($6.40) by $1.38. On average, sell-side analysts forecast that Autonomix Medical will post -20.17 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

AMIX has been the subject of several research reports. Zacks Research raised shares of Autonomix Medical to a “hold” rating in a research note on Tuesday, June 2nd. Weiss Ratings raised shares of Autonomix Medical from a “sell (e)” rating to a “sell (e+)” rating in a research report on Tuesday, July 28th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $42.00.

About Autonomix Medical

Autonomix Medical, Inc, a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.